Brought to you by 
Meda pays SEK21bn for family owned Italian company Rottapharm
30 Sep 2020
Executive Summary
Meda AB, which recently fought off two unsolicited takeover bids from Mylan Inc. (the latest of which would have valued Meda at $6.7bn), paid SEK21bn ($3.1bn) for private, family owned Italian pharmaco Rottapharm SPA. The transaction excludes Rottapharm Biotech SRL, a separate entity (created in 2008 around assets purchased from Lay Line Genomics) focused on developing antibodies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Meda pays SEK21bn for family owned Italian company Rottapharm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice